The ELISpot and FluoroSpot Assay Market is Segmented by Product (Analyzers, Assay Kits, and Ancillary Products), Application (Research and Diagnostics), End-User (Hospitals & Clinical Labs, Biopharmaceutical Companies, and Research Institutes) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
ELISpot and FluoroSpot Assay Market Overview
The global ELISpot and FluoroSpot Assay market size was estimated at USD 295.64 million in 2023 and is projected to reach USD 503.41 million in 2030 at a CAGR of 7.9% during the forecast period 2023-2030.
Due to its excellent sensitivity, the enzyme-linked immunospot (ELISpot) test is frequently used to identify different illness conditions. They're incredibly adaptable and frequently employed to gauge antigen-specific T lymphocytes in mice and people. Because they may measure a wide range of immune responses and cellular immune-related activities, these tests are increasingly recommended and well-liked. Thus, ELISpot has now undergone a considerable transformation from a research tool to a clinical test that is often used in laboratories. Several ELISpot tests, including as those for IFN-gamma, Granzyme B, TGF-Beta 1, Fluorescent, and others, are used for a variety of diagnostic purposes. In order to conduct the FluoroSpot test, a 96-well plate containing a combination of monoclonal antibodies and PVDF membranes is used as the assay platform. For secreted proteins like cytokines from active cells, the ELISpot and FluoroSpot are ideally suited.
The worldwide ELISpot and FluoroSpot assay market is divided into infectious illnesses, cancer, autoimmune disorders, allergies, and others on the basis of diseases. The infectious illness is further divided into categories like COVID-19, the flu, HIV, and others. Due to the rising prevalence of chronic infectious illnesses and the higher productivity associated with the use of ELISpot and FluoroSpot tests, the infectious diseases sector is anticipated to dominate the ELISpot and FluoroSpot assay market in 2021. Diagnostic and research applications make up the segments of the global ELISpot and FluoroSpot assay market. Infectious illnesses, transplants, and other conditions are further divided into sub-segments within the diagnostic applications. The research applications are further divided into the following categories: cancer research, clinical trials, vaccine development, and others.
Get a Sample Copy of the ELISpot and FluoroSpot Assay Market Research Report: https://www.delvens.com/get-free-sample/elispot-and-fluorospot-assay-market
The COVID-19 pandemic had a major influence on healthcare systems across the world, including the markets for ELISpot and FluoroSpot assays. The FluoroSpot assay revealed that COVID-19 patients had the lowest antibody response, whereas three individuals (C4, C5, and C7) had the strongest T-cell responses. ELISpot and FluoroSpot tests are frequently used to evaluate COVID-19 patients' T- and B-cell immunity against SARS-CoV-2. Nonetheless, the industry has recorded a modest fall because COVID-19 instances decreased last year.
Delvens Industry Expert's Standpoint
The development of new vaccines to combat drug-resistant strains, the rise in the prevalence of chronic diseases worldwide, and technical advancements in ELISpot and FluoroSpot analyzers and assay kits are anticipated to propel market expansion. ELISpot is a vital technique in the creation of vaccines against a number of diseases, such as AIDS, TB, malaria, cancer, and the flu. In clinical investigations to assess vaccinations, the ELISpot test is frequently employed. In comparison to enzyme-linked immunoassays (ELISA) and flow cytometry, the FluoroSpot test based on the ELISpot was found to be more accurate in a June 2021 paper published in the BMC Infectious Diseases Journal (FCM). More than 15 million individuals between the ages of 30 and 69 pass away from NCDs, with low- and middle-income nations accounting for 85% of these early fatalities. As a result, the use of ELISpot and FluroSpot tests for diagnostic purposes is anticipated to expand due to the rising prevalence of chronic illnesses, fueling market expansion.
Key Findings
- On the basis of application, the worldwide ELISpot and FluoroSpot test market is divided into diagnostic and research applications based on application. Infectious illnesses, transplants, and other conditions are further divided into sub-segments within the diagnostic applications. The research applications are further divided into the following categories: cancer research, clinical trials, vaccine development, and others. The market for ELISpot and FluoroSpot assays is predicted to be dominated by the diagnostic application sector in 2021 as a result of the rise in chronic infectious illnesses and the usage of point-of-care diagnostics during the pandemic.
- On the basis of end user, the worldwide ELISpot and FluoroSpot assay market is divided into hospitals and clinics, research institutions, pharmaceuticals firms, and other end users based on end user. The ELISpot and FluoroSpot assay market is anticipated to be dominated by hospitals and clinics in 2021 as a result of the availability of improved diagnostic infrastructure and healthcare insurance policies.
- The global ELISpot and FluoroSpot assay market is divided into direct tender and retail sales based on distribution. Due to the availability of a greater number of contacts, increased cost savings, and the assurance of compliance engagements, the direct tender sector is anticipated to dominate the market for ELISpot and FluoroSpot assays in 2021.
- On the basis of product type, the worldwide ELISpot and FluoroSpot test market is divided into three categories based on the kind of product: assay kits, analyzers, and supplemental or ancillary products. The test kit products are further divided into t-cell and cell assays. Due to the increasing demand for cell-based assays in drug discovery and the usage of T-cell assays in cancer research, the assay kits sector is anticipated to dominate the ELISpot and FluoroSpot test market in 2021.
- The global ELISpot and FluoroSpot assay market is divided into the following regions: the United States, Canada and Mexico; Germany, France, the United Kingdom; Italy; Spain; Russia; Belgium; Turkey; Switzerland; the Netherlands; and the rest of Europe; Japan; China; Australia; South Korea; India; Singapore; Thailand; Indonesia; Malaysia; the Philippines; and the rest of Asia-Pacific; Brazil; Argentina; and South Africa; as well as the rest of the Middle East and Africa.
Inquire before you purchase to increase your business' revenue: https://www.delvens.com/Inquire-before-buying/elispot-and-fluorospot-assay-market
ELISpot and FluoroSpot Assay Market Regional Analysis
North America to Dominate the Market
- Due to the widespread availability of ELISpot kits and the usage of the assay kits for vaccine research, North America is predicted to dominate the market.
- Due to the availability of FDA-approved ELISpot and FluoroSpot assay kits, the existence of health reimbursement policies, the growth in chronic infections, and the rise in the older population, the U.S. is leading the worldwide ELISpot and FluoroSpot assay in the North America area.
ELISpot and FluoroSpot Assay Market Competitive Landscape
- Oxford immunotec
- Cellular Technology Limited
- Mabtech
- Becton
- Abcam plc
- Bio-Techne
- Mikrogen Diagnostik
- Autoimmun Diagnostika
- U-CyTech
- Medix Biochemica
- Merck KGaA
- Bio-Sys GmbH
- Anogen-Yes Biotech Laboratories
- Abnova Corporation
- Biorbyt Ltd
- Tokyo Chemical Industry
- MP BIOMEDICALS
- BOC Sciences
- ZenBio,Inc
- Jackson ImmunoResearch Inc
- Krishgen Biosysystems
- National Analytical Corporation
- Stemcell Technologies
- Serva Electrophoresis GmbH
ELISpot and FluoroSpot Assay Market Recent Developments
- In June 2022, in order to develop a molecular diagnostic test for the Monkeypox virus, an uncommon disease brought on by a virus closely related to the smallpox virus, BD and CerTest Biotec worked together. The partnership seeks to enhance the detection and treatment of infections with monkeypox. The assay will use the BD MAXTM open system reagent suite as part of the cooperation to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAXTM System. Users of BD MAXTM will have access to the test, which might increase knowledge of the disease's widespread distribution across the world.
- In April 2022, A service for B-cell ELISpot assays was introduced by ProImmune Ltd. The body's immune defense against viruses, immunological modulators, vaccinations, and therapeutic medications depends heavily on B cells, which are analyzed with the B cell ELISpot test. By counting the amount of B cells that produce a particular antibody in response to a given stimulation, researchers may gauge the effectiveness of vaccinations or the strength of medicinal medications.
Reasons to Acquire in the ELISpot and FluoroSpot Assay Market
- Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
- Gain authentic and granular data access for the ELISpot and FluoroSpot Assay Market to understand the trends and the factors involved in changing market situations.
- Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
- In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Direct Purchase of Underwater Concrete Market Report Research Report: https://www.delvens.com/checkout/elispot-and-fluorospot-assay-market
Frequently Asked Questions
What are the years considered to study ELISpot and FluoroSpot Assay Market intelligence report?
What is the compound annual growth rate (CAGR) of the ELISpot and FluoroSpot Assay Market?
Which region holds the largest market share in ELISpot and FluoroSpot Assay Market?
Which region is the fastest growing in ELISpot and FluoroSpot Assay Market?
Who are the major players in ELISpot and FluoroSpot Assay Market?
Browse Related Reports:
Diagnostic Imaging Services Market – Trends Forecast Till 2030
Diagnostic Imaging Services Market, By Procedure (Computed Tomography, MRI, and X-ray), By Application (Neurology, Oncology, and Cardiology), By Service Provider (Diagnostic Centres, Hospitals, Ambulatory Surgical Centers, and Others), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Dental Implants Market – Trends Forecast Till 2030
Dental Implants Market, By Part (Fixture and Abutment), Material (Titanium Implants and Zirconium Implants), Design (Tapered Implants, and Parallel Walled Implants), Type (Root-Form Dental Implants, Parallel-Walled Dental Implants), Price (Premium Implants, Value Implants, Discounted Implants), End User (Hospitals and Clinics, Dental Laboratories, Other Facilities) And Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Medical Cannabis Market – Trends Forecast Till 2030
Medical Cannabis Market, by Product (Oil, Medical Cannabis Capsules, Patch, Whole Flower, Ground Flower, Vape Pen, Dried Medical Cannabis, Creams & Moisturizer, Masks & Serum, Cleanser, and Others), Source (Natural and Synthetic), Species (Cannabis Indica, Sativa, and Hybrid), Application (Alzheimer’s Disease, Appetite Loss, Cancer, Inflammatory Bowel Diseases, Eating Disorders, Epilepsy, Autism, Mental Health Conditions, Multiple Sclerosis, Pain Management, Nausea, Muscle Spasms, Wasting Syndrome (Cachexia), Elevate Mood, Depression and Sleep Disorders, Anxiety, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
Overview:The ELISpot and FluoroSpot Assay market report has various growth pockets that can be explored in the coming years to boost a growth worth USD 287 million by 2023.
Request Sample Copy:https://www.marketresearchfuture.com/sample_request/6948Segmentation:The global report on the ELISpot and FluoroSpot Assay market has been studied on the basis of a segmentation that includes an application, product, and end-user.
This will help in the better strategy-making process in the coming years.
By product, the global market for the ELISpot and FluoroSpot Assay has been studied by segmenting it into the analyzer, various assay kits, and ancillary products.
By end-user, the report covering the ELISpot and FluoroSpot Assay market includes ambulatory surgical centers, hospitals & clinics, research centers, diagnostic centers, and others.
Regional Analysis:North America is structurally superior when it comes to the healthcare sector.
Global ELISpot and FluoroSpot Assay Market Research Report, by Product (Assay Kit, Ancillary Products), Application (Transplant, Vaccines), End-User (Hospitals and Clinics, Ambulatory Surgical Centres, Diagnostic Centres, Research Centers) – Forecast Till 2027Market Highlights:The ELISpot and FluoroSpot Assay are using to detect various antibodies, cytokines, and granzymes.
These kits are applicable for early diagnose diseases such as TB and tick-borne diseases.
The global ELISpot and FluoroSpot assay market were estimated USD 135 million in 2017 and expected to reach USD 287 million by 2023 at a CAGR of 16.2% during the forecast period.
However, factors such as high cost of ELISpot and FluoroSpot assay, lack of skilled technicians and alternative techniques are expected to hinder the growth of ELISpot and FluoroSpot assay market during the forecast period.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/6948Segmentation:The Global ELISpot and FluoroSpot Assay Market.is segmented on the basis of product, application, and end-user.
On the basis of end-user, the ELISpot and FluoroSpot Assay market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.On the basis of region, the global ELISpot and FluoroSpot Assay market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.Regional Analysis:The Americas is the largest in the market owing to the increasing prevalence of chronic & viral diseases, rising geriatric population, and increasing number of pharmaceutical manufacturing units in America will boost the demand for ELISpot and FluoroSpot Assay kit.
According to the Centers for Disease Control and Prevention 2017, it was reported that 90.6% of children aged 19-35 months were vaccinated with Chickenpox vaccine and 81.8% with Pneumococcal conjugate vaccine in the US.
Growth in this ELISpot and FluoroSpot Assay Market is driven by the rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers.
[111 Pages Report] The ELISpot and FluoroSpot Assay market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2% during the forecast period.ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) - Global Forecast to 2023What drives the Market?Rising Global Incidence of Chronic DiseasesIncreasing Vaccine Development to Address the Challenge of Antimicrobial ResistanceTechnological Advancements in ELISpot and FluoroSpot Assay Kits and AnalyzersOn the other hand, the availability of alternative detection technologies is expected to limit market growth during the forecast period.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584“Asia Pacific to grow at the highest rate during the forecast period (2018–2023)” The ELISpot and FluoroSpot market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).
While North America is expected to dominate the market in 2018, Asia Pacific is expected to register the highest CAGR in the market during the forecast period.
Growth in APAC is largely driven by the large patient population and high prevalence of chronic diseases in this region.Key Market Players Some of the prominent players in the ELISpot and FluoroSpot are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK).Oxford Immunotec is the leading player in the ELISpot and FluoroSpot market.
The company focuses on the development of diagnostic kits for the early detection of diseases such as TB and tick-borne diseases.
In 2017, it spent around 16% of its revenue on R activities, which is higher than most of its counterparts.Cellular Technology Limited (CTL) is among the pioneers of the ELISpot and FluoroSpot assays.
The increasing prevalence of chronic disorders, increasing technological advancements in the assay kits and analyzers, and increasing research in the field of vaccines are expected to be the primary factors affecting the market.
Market Size – USD 123.5 Million in 2018, Market Growth - CAGR of 15.9%, Market Trends– The increasing advancements in the field of diagnostics and cancer research could be some factors responsible for market growth According to the current analysis of Reports and Data, the ELISpot and Fluorospot Assay Marketwas valued at USD 123.5 million in 2018 and is expected to reach USD 408.8 million by the year 2026, at a CAGR of 15.9%.
The technique is antibody-based, wherein the microplates used in the assay are covered by specific antibodies that detect significant proteins from the sample.
Various companies have invested in the R sector to improve the assay techniques and to gain reliable results.
There is a significant increase in healthcare expenditure in developing countries, which could contribute to the growth of the industry.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2697The report provides a complete analysis of the global ELISpot and Fluorospot Assay) market with important details about the key market players from insightful primary and secondary research data.
The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Oxford Immunotec, Cellular Technologies, Mabtech, Becton, Dickinson and Company, Abcam, Bio-Techne, U-Cytech Biosciences, Lophius Biosciences GmbH, and Biotech Investissement Group.Further key findings from the report suggestDifferent companies continue to be leaders since the introduction of ELISpot and Fluorospot assay techniques.
